Nina Cosdon

Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?

This study explores the effectiveness of PCR and toxin EIA testing in predicting C difficile infection (CDI) outcomes. The research reveals that patients with negative toxin results were less likely to experience CDI recurrence within 30 days.

Rebyota, the first FDA-approved microbiota-based live biotherapeutic for preventing recurrent Clostridioides difficile infection (rCDI), has been the subject of a groundbreaking safety analysis.

Patients with cancer, cancer survivors, and matched controls maintained immunity against severe COVID-19 for at least 5 months after a third or fourth vaccine dose.

Workplace exposure and living conditions were associated with higher COVID-19 risk, while previous infection, age 65 or older, and Black/African American race were correlated with lower COVID-19 rates.

This study found a substantial increase in Alzheimer's-related deaths during the initial year of the pandemic due to limited access to healthcare, social isolation, and disrupted care routines. However, the second year brought positive developments with prevention strategies and vaccinations, leading to a substantial decline in excess deaths.

More symptoms, older age, and longer hospitalization time increased the risk of post-COVID-19 conditions (long COVID) in children.

Which COVID-19 vaccine is associated with Guillain-Barré Syndrome? What's the newest C difficile therapy? Contagion's weekly infectious disease recap has you covered.

In a major breakthrough, Gilead’s remdesivir (Veklury) becomes the first COVID-19 antiviral to be FDA-approved for patients with severe renal disease.

Neuropilin-1 enables COVID-19 to enter human cardiomyocytes, accounting for increased proteases activity and apoptotic markers that lead to cell damage and apoptosis.

Find out why the FDA requested additional data and what this means for dengue prevention.

Though rare, Guillain-Barré syndrome can occur after vaccination. Did Pfizer-BioNTech, Moderna, or Janssen COVID-19 vaccination increase the risk of Guillain-Barré syndrome?

This examination of vaccine introductions worldwide reveals significant gaps in access, especially in low-income countries.

Researchers investigated abatacept, cenicriviroc, and infliximab, but found that these medications did not significantly impact the time to recovery from COVID-19 pneumonia compared to placebo.

These study findings highlight higher in-hospital mortality rates for patients with preventable conditions during COVID-19.

6 malaria cases were confirmed in Florida and 1 in Texas, with no connection to international travel.

In a comprehensive economic evaluation, researchers assessed the cost-effectiveness of monoclonal antibodies as a preventive strategy for COVID-19.

Stay informed about the long-term effects of COVID-19, prevention strategies for recurrent C diff, and the emerging threat of drug-resistant Candida auris.

Infants with non–COVID-19 viruses had a lower risk of UTIs, bacteremia, and bacterial meningitis, while those with COVID-19 had the lowest risk.

The findings showed that heterologous vaccination, or mixing different vaccines, was safe and effective, with the Novavax vaccine (NVX-CoV2373) providing enhanced protection against the Omicron variant.

Moderna's RSV vaccine (mRNA-1345) moves closer to regulatory approval with positive data and key submissions to the US FDA, European Medicines Agency, Switzerland's Swissmedic, and Australia's Therapeutic Goods Administration.

Among people living with hepatitis C virus (HCV), viral clearance was only 34%. Cure rates were even lower among uninsured persons younger than 40.

FMT is a promising intervention for immunocompetent patients with recurrent C difficile infection. However, the safety of FMT remains inconclusive due to limited data on serious adverse events and mortality.

From FDA recalls to a new COVID-19 variant, infectious disease news did not slow down in June. Catch up with Contagion's monthly recap of our most-clicked articles.

Aerobic activity and muscle strengthening exercises reduced the risk of pneumonia or influenza mortality, even when the exercises were completed less frequently than recommended.

As of today, the new GSK and Pfizer RSV vaccines are authorized for adults 60 years and older. With CDC Director Dr. Rochelle Walensky’s endorsement, the vaccines are expected to be available as soon as this fall.

Receiving meals after hospital discharge significantly reduced the risk of 30-day rehospitalization and death in patients hospitalized with heart failure and other acute medical conditions.

New data from AIDSVu show significant disparities in the usage of HIV pre-exposure prophylaxis (PrEP). Black and Hispanic/Latinx Americans are underrepresented among PrEP users, despite accounting for a significant portion of new HIV diagnoses.

There was a lower risk of Omicron infection for each 10-fold increase in preinfection IgG, and for each 2-fold increase in neutralizing antibody titers.

In Indiana, COVID-19 patients with chronic obstructive pulmonary disease, cardiovascular disease, and type 2 diabetes had significantly higher mortality rates than COVID-19 patients without these comorbidities.